Health care utilization and costs associated with switching from DPP-4i to GLP-1RA or SGLT2i: an observational cohort study

BACKGROUND: Because of improved clinical outcomes, recent American Diabetes Association guidelines recommend the use of newer antidiabetic agents—glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i)—by those with cardiovascular disease. It is unc...

Descripción completa

Detalles Bibliográficos
Autores principales: Newman, Terri Victoria, Munshi, Kiraat D, Neilson, Lynn M, Good, Chester B, Swart, Elizabeth C S, Huang, Yan, Henderson, Rochelle, Parekh, Natasha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391293/
https://www.ncbi.nlm.nih.gov/pubmed/33769857
http://dx.doi.org/10.18553/jmcp.2021.27.4.435

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391293/
https://www.ncbi.nlm.nih.gov/pubmed/33769857
http://dx.doi.org/10.18553/jmcp.2021.27.4.435

Ejemplares similares